The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Open accessAbstract
BACKGROUND: The combination of radiotherapy plus long-term medical suppression of androgens (> or = 2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer. METHODS: We randomly assigned patients with locally advanced prostate cancer who had received external-beam radiotherapy plus 6 months of androgen suppression to two groups, one to receive no further treatment (short-term suppression) and the other to receive 2.5 years of further treatment with a luteinizing hormone-releasing hormone agonist (long-term suppression). An outcome of noninferiority of short-term androgen suppression as compared with long-term suppression required a hazard ratio of more than 1.35 for overall survival, with a one-sided alpha level of 0.05. An interim analysis showed futility, and the results are presented with an adjusted one-sided alpha level of 0.0429. RESULTS: A total of 1113 men were registered, of whom 970 were randomly assigned, 483 to short-term suppression and 487 to long-term suppression. After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died; the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group. The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively; the observed hazard ratio was 1.42 (upper 95.71% confidence limit, 1.79; P=0.65 for noninferiority). Adverse events in both groups included fatigue, diminished sexual function, and hot flushes. CONCLUSIONS: The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer. (ClinicalTrials.gov number, NCT00003026.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Cox, J. D., Stetz, J., & Pajak, T. F. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00060-c · Cited by 4,792
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 4,019
The Statistical Analysis of Failure Time Data
Kalbfleisch, J. D., & Prentice, R. L. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781118032985 · Cited by 3,219
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Self-citationBolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Self-citationDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Pilepich, M. V., Winter, K., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 913
Widmark, A., Klepp, O., Solberg, A., Damber, J.-E., Angelsen, A., Fransson, P., Lund, J.-Å., Tasdemir, I., Hoyer, M., Wiklund, F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61815-2 · Cited by 876
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., Venkatesan, V., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9021 · Cited by 688
Roach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy
Braga-Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J., & Basaria, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 585
Potosky, A. L., Knopf, K., Clegg, L. X., Albertsen, P. C., Stanford, J. L., Hamilton, A. S., Gilliland, F. D., Eley, J. W., Stephenson, R. A., & Hoffman, R. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3750 · Cited by 251
Group sequential designs using a family of type I error probability spending functions
Hwang, I. K., Shih, W. J., & De Cani, J. S. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091207 · Cited by 248
五味, 光., 小塚, 拓., & 山下, 孝. (2005) · Mebio oncology · Cited by 192
Adverse events associated with hormonal therapy for prostate cancer.
Kumar, R., Barqawi, A. B., & Crawford, E. D. (2005) · Europe PMC (PubMed Central) · Cited by 117
Com-Nougué, C., Rodary, C., & Patte, C. (1993) · Statistics in Medicine · doi:10.1002/sim.4780121407 · Cited by 101
Lubeck, D. P., Grossfeld, G. D., & Carroll, P. R. (2001) · Urology · doi:10.1016/s0090-4295(01)01250-x · Cited by 91
Health-related quality of life after treatment for localized prostate cancer
Litwin, M. S. (1995) · Cancer · doi:10.1002/1097-0142(19950401)75:7+<1972::aid-cncr2820751636>3.0.co;2-p · Cited by 41
D'Amico, A. V. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8260 · Cited by 11
Cited by
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Self-citationMottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Self-citation
Metadata
- Authors
- Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., Kariakine, O., van der Steen-Banasik, E. M., Musat, E., Piérart, M., Mauer, M. E., & Collette, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-11
- Volume
- 360
- Issue
- 24
- Pages
- 2516-2527
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985587689
- Cited by
- 970
- References
- 27
- FWCI
- 69.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.